Recruiting Alzheimers Disease Studies in Paris
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
This phase III trial studies how well mitotane alone works compared to mitotane with cisplatin and etoposide when given after surgery in treating patients with adrenocortical cancer that has a high ri...
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have ...
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours. The participants in this study will have...
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adult Male Subjects With Cerebral Adrenoleukodystrophy
A Clinical Study to Assess the Efficacy and Safety of Leriglitazone in Adults Male Subjects with Cerebral Adrenoleukodystrophy....
Phase 1/2 Clinical Trial of LY3884963 in Patients With Frontotemporal Dementia With Progranulin Mutations (FTD-GRN)
Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin prot...
About Alzheimers Disease Clinical Trials in Paris
Alzheimer's disease is a progressive brain disorder that destroys memory, thinking skills, and the ability to carry out daily tasks. It is the most common cause of dementia, affecting over 6.7 million Americans age 65 and older. The disease is characterized by amyloid-beta plaques and tau tangles in the brain. Recent FDA approvals of anti-amyloid antibodies like lecanemab (Leqembi) and donanemab have opened a new era of disease-modifying treatments. Clinical trials are now exploring next-generation amyloid-clearing therapies, tau-targeting treatments, anti-inflammatory approaches, and combination strategies. Early-stage patients with mild cognitive impairment or early Alzheimer's are frequently sought for enrollment, and many trials now use blood-based biomarkers for screening.
There are currently 5 alzheimers disease clinical trials recruiting participants in Paris, PARIS. These studies are seeking a combined 615 participants. Research is being sponsored by M.D. Anderson Cancer Center, Ipsen, Minoryx Therapeutics, S.L. and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Alzheimers Disease Clinical Trials in Paris — FAQ
Are there alzheimers disease clinical trials in Paris?
Yes, there are 5 alzheimers disease clinical trials currently recruiting in Paris, PARIS. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Paris?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Paris research site will contact you about next steps.
Are clinical trials in Paris free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Paris studies also compensate for your time and travel.
What alzheimers disease treatments are being tested?
The 5 active trials in Paris are testing new therapies including novel drugs, biologics, and treatment approaches for alzheimers disease.
Data updated March 2, 2026 from ClinicalTrials.gov